Nuo Therapeutics Inc
OTC:AURX

Watchlist Manager
Nuo Therapeutics Inc Logo
Nuo Therapeutics Inc
OTC:AURX
Watchlist
Price: 1.9 USD Market Closed
Market Cap: 91.4m USD

Net Margin

-93.1%
Current
Improving
by 649.4%
vs 3-y average of -742.4%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-93.1%
=
Net Income
$-2.4m
/
Revenue
$2.6m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-93.1%
=
Net Income
$-2.4m
/
Revenue
$2.6m

Peer Comparison

Country Company Market Cap Net
Margin
US
Nuo Therapeutics Inc
OTC:AURX
89m USD
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.2B USD
Loading...
US
Seagen Inc
F:SGT
39.3B EUR
Loading...
US
IQVIA Holdings Inc
NYSE:IQV
40.5B USD
Loading...
US
Gartner Inc
NYSE:IT
16.8B USD
Loading...
IE
ICON PLC
NASDAQ:ICLR
13.9B USD
Loading...
US
Ionis Pharmaceuticals Inc
NASDAQ:IONS
12.3B USD
Loading...
US
Charles River Laboratories International Inc
NYSE:CRL
10.8B USD
Loading...
US
Halozyme Therapeutics Inc
NASDAQ:HALO
8.4B USD
Loading...
US
Cytokinetics Inc
NASDAQ:CYTK
7.6B USD
Loading...
UK
Verona Pharma PLC
NASDAQ:VRNA
7.4B USD
Loading...
No Stocks Found

Market Distribution

Lower than 85% of companies in the United States of America
Percentile
15th
Based on 15 072 companies
15th percentile
-93.1%
Low
-4 418 600% — -9.6%
Typical Range
-9.6% — 11.3%
High
11.3% — 1 135 400%
Distribution Statistics
the United States of America
Min -4 418 600%
30th Percentile -9.6%
Median 3.1%
70th Percentile 11.3%
Max 1 135 400%

Nuo Therapeutics Inc
Glance View

Market Cap
91.4m USD
Industry
N/A

Nuo Therapeutics, Inc. is a biomedical company. The company is headquartered in Houston, Texas and currently employs 7 full-time employees. The company went IPO on 2017-01-19. The firm's Aurix System is a biodynamic hematogel that harnesses a patient's innate regenerative abilities for the management of a variety of wounds. The firm commercializes cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing. The Company’s Aurix point of care technology for the safe and efficient separation of autologous blood to produce a platelet-based therapy for the chronic wound care market. The firm is marketing its products primarily within the United States. Nuo Therapeutics' s Aurix System produces a platelet rich plasma (PRP), gel at the point of care using the patient’s own platelets and plasma. The Aurix comprises a natural, endogenous complement of protein and non-protein signal molecules that contribute to effective healing.

AURX Intrinsic Value
0.17 USD
Overvaluation 91%
Intrinsic Value
Price
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-93.1%
=
Net Income
$-2.4m
/
Revenue
$2.6m
What is Nuo Therapeutics Inc's current Net Margin?

The current Net Margin for Nuo Therapeutics Inc is -93.1%, which is above its 3-year median of -742.4%.

How has Net Margin changed over time?

Over the last 3 years, Nuo Therapeutics Inc’s Net Margin has increased from -7 700% to -93.1%. During this period, it reached a low of -7 700% on Aug 30, 2022 and a high of -93.1% on Oct 30, 2025.

Back to Top